Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

NCT02001623CompletedPHASE1, PHASE2INTERVENTIONAL

Summary

The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.

Key Facts

Lead Sponsor

Seagen Inc.

Enrollment

195

Start Date

2013-11-30

Completion Date

2019-05-02

Study Type

INTERVENTIONAL

Official Title

First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

Interventions

Tisotumab Vedotin (HuMax-TF-ADC)

Conditions

Ovary CancerCervix CancerEndometrium CancerBladder CancerProstate Cancer (CRPC)Esophagus CancerLung Cancer(NSCLC)Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Eligibility

Age Range

18 Years+

Sex

ALL

Inclusion Criteria:

\- Patients with relapsed, advanced and/or metastatic cancer who have failed available standard treatments or who are not candidates for standard therapy.

Patients must have measurable disease

* Age ≥ 18 years.
* Acceptable renal function
* Acceptable liver function
* Acceptable hematological status (without hematologic support
* Acceptable coagulation status
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Life expectancy of at least three months.
* A negative serum pregnancy test (if female and aged between 18-55 years old).
* Women who are pregnant or breast feeding are not to be included.
* Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of HuMax-TF-ADC.
* Following receipt of verbal and written information about the study, patients must provide signed informed consent before any study-related activity is carried out.

Exclusion Criteria:

* Known past or current coagulation defects.
* Ongoing major bleeding,
* Have clinically significant cardiac disease
* A baseline QT interval as corrected by Fridericia's formula (QTcF) \> 450 msec, a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left bundle branch block form) or an incomplete left bundle branch block.
* Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support within one week or pegylated G-CSF within two weeks before the Screening Visit.
* Have received a cumulative dose of corticosteroid ≥ 100 mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.
* Major surgery within six weeks or open biopsy within 14 days before drug infusion.
* Plan for any major surgery during treatment period.
* Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain metastases or stroke.
* Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within four weeks or five half lives, whichever is longest, before first infusion.
* Prior treatment with bevacizumab within twelve weeks before the first infusion.
* Radiotherapy within 28 days prior to first dose.
* Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.
* Known past or current malignancy other than inclusion diagnosis, except for:
* Cervical carcinoma of Stage 1B or less.
* Non-invasive basal cell or squamous cell skin carcinoma.
* Non-invasive, superficial bladder cancer.
* Prostate cancer with a current PSA level \< 0.1 ng/mL.
* Any curable cancer with a complete response (CR) of \> 5 years duration.
* Known human immunodeficiency virus seropositivity.
* Positive serology (unless due to vaccination or passive immunization due to Ig therapy) for hepatitis B
* Positive serology for hepatitis C based on test at screening.
* Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.
* Inflammatory lung disease including moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring chronic medical therapy.
* Ongoing acute or chronic inflammatory skin disease.

Outcome Measures

Primary Outcomes

Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events

Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.

Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events

Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.

Secondary Outcomes

Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values

Number of participants with markedly abnormal hematology values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 hematology value. A markedly abnormal hematology value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values

Number of participants with markedly abnormal coagulation values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 coagulation value. A markedly abnormal coagulation value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values

Number of participants with markedly abnormal biochemistry results were defined as all participants who experienced at least 1 CTCAE grade \>= 3 biochemistry value. A markedly abnormal biochemistry value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest

Bleeding adverse events of special interest included treatment emergent adverse events with preferred terms within the following standardised MedDRA queries (SMQs): Haemorrhage terms, excluding laboratory terms SMQ \[20000039\] (Broad) and Haemorrhage, laboratory terms SMQ \[20000040\] (Narrow). Bleeding adverse events of special interest were evaluated according to the NCI-CTCAE version 4.03. Bleeding events of all grades are included. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event

Peripheral neuropathy events of special interest were evaluated according to the NCI-CTCAE version 4.03. Peripheral neuropathy events of all grades are included in the numbers below. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF

Pharmacokinetic (PK) parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not collected to report or calculate clearance for the expansion phase.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the volume of distribution of tisotumab vedotin and total HuMax-TF for the dose expansion part.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation and Expansion Part: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation Part: Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was only analyzed in the dose escalation part of the study. Data was not planned to be collected for the AUC0-inf of tisotumab vedotin and total HuMax-TF for the dose expansion part.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. t1/2 was only analyzed for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)

PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation Part: AUC0-inf of Free MMAE

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf was not calculated where the percentage of the AUC that was due to the extrapolation was more than 20%.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation and Expansion Part: Cmax of Free MMAE

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation and Expansion Part: Tmax of Free MMAE

PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE

PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.

Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)

Dose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin

Participants who met the criterion for positive ADAs on treatment were defined as participants who were negative at baseline and had at least one positive post-baseline result, or participants who were positive at baseline and had at least one post baseline result with a titer higher than baseline.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage

Anti-tumor activity measured by the number of participants who experienced tumor shrinkage was not planned to be collected for the dose expansion part.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements

Anti-tumor activity measured by maximum reduction among available post-baseline sum of lesion measurements was not planned to be collected for the dose escalation part.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA)

PSA was only assessed in participants with castrate-resistant prostate cancer.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125

In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Part: Objective Response Rate

Objective Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Response assessment was investigator based for the escalation part and Independent Review Committee (IRC) based for the expansion part.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Escalation and Expansion Part: Disease Control Rate

Disease control rate was defined as the percentage of participants with CR, PR or stable disease (SD) as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease.

Time frame: At 6, 12, 24 and 36 weeks

Dose Escalation and Expansion Part: Progression Free Survival (PFS)

PFS was defined as the time in weeks from Day 1 in Cycle 1 to first disease progression or death, whichever occurred earliest, as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Progression as defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase from nadir in the sum of diameters of target lesions, unequivocal progression in non-target lesions, or the appearance of new lesions

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Dose Expansion Part: Duration of Response (DOR)

DOR was defined as the median time in weeks from when confirmed response was first documented until the first documented disease progression, or death from any cause, whichever was earliest as assessed by the investigator. A responder was defined as any participant with a best overall response of confirmed CR or PR.

Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks

Locations

University of California Irvine Medical Center (UCIMC), Orange, United States

Yale Cancer Center, New Haven, United States

University of Miami, Miami, United States

University Gynecologic Oncology, Atlanta, United States

Comprehensive Cancer Centers of Nevada, Las Vegas, United States

Sarah Cannon Research Institute, Nashville, United States

MD Anderson Cancer Center, Houston, United States

University of Virginia, Charlottesville, United States

Universitair Ziekenhuis Antwerpen, Edegem, Belgium

Universitair Ziekenhuis Leuven, Leuven, Belgium

Grand Hôpital de Charleroi, Charleroi, Belgium

Centre Hospitalier Universitaire Ambroise Paré, Mons, Belgium

CHU UCL Namur - site Godinne, Yvoir, Belgium

Saint-Luc University Hospital, Brussels, Belgium

CHU de Liège, Liège, Belgium

CHU UCL Namur - Sainte Elisabeth, Namur, Belgium

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Herlev and Gentofte Hospital, Herlev, Denmark

Karolinska Universitetssjukhuset, Stockholm, Sweden

Lungemedicinska Kliniken, Linköping, Sweden

The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

University College London Hospitals, London, United Kingdom

Sarah Cannon Research Institute - London, London, United Kingdom

Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Velindre NHS Trust, Cardiff, United Kingdom

Beatson Cancer Centre, Glasgow, United Kingdom

Guys hospital, London, United Kingdom

The Christie NHS Foundation Trust, Manchester, United Kingdom

Linked Papers

2025-10-03

Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin

Tisotumab vedotin (TV), a tissue factor-directed antibody-drug conjugate (ADC), is approved in the US at 2.0 mg/kg every 3 weeks (Q3W) for adult patients with recurrent or metastatic cervical cancer following disease progression on or after chemotherapy. Previous logistic regression analysis showed a positive association between TV exposure and ocular adverse events (OAEs), which were identified as prespecified AEs of interest in TV clinical studies. To further optimize TV dose from a safety perspective, we developed a discrete-time Markov model (DTMM) to characterize exposure-response (E-R) relationships of exposures of both ADC and the microtubule-disrupting agent monomethyl auristatin E to the incidence, severity, and longitudinal time course of grade ≥ 2 OAEs in patients with advanced solid tumors. A total of 757 patients who received TV as monotherapy or combination (with carboplatin, bevacizumab, or pembrolizumab) across seven clinical studies were included in this analysis. Of multiple covariates modeled, implementation of an eye care plan was the only covariate to significantly reduce risk of grade ≥ 2 OAEs. The DTMM suggested an association between ADC exposure and risk of grade ≥ 2 OAEs. Based on the totality of data from clinical outcomes, pharmacokinetics, and E-R analyses, as well as DTMM modeling results, TV 1.7 mg/kg every 2 weeks may provide higher efficacy with slightly increased risk of OAEs compared with 2.0 mg/kg Q3W, although these OAEs are manageable with an appropriate eye care plan. ClinicalTrials.gov ID (first submission): NCT03485209 (2018-03-08), NCT03657043 (2018-08-22), NCT03438396 (2018-02-08), NCT03786081 (2018-12-13), NCT03913741 (2019-03-29), NCT02001623 (2013-11-14), and NCT02552121 (2015-09-14).

2019-12-03

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Abstract Purpose: Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody–drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase I/II study (NCT02001623). Patients and Methods: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. Results: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab + doublet chemotherapy. Fifty-one percent of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% [95% confidence interval (CI): 13%−37%]. Median duration of response (DOR) was 4.2 months (range: 1.0+−9.7); four patients responded for &amp;gt;8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%−43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%−35%), median DOR of 6.0 months (range: 1.0+−9.7), and 6-month PFS rate of 40% (95% CI: 24%−55%). Tissue factor expression was confirmed in most patients; no significant association with response was observed. Conclusions: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.

Linked Investigators

David S. Hong

Dr. David Hong received a Bachelor’s degree from Yale University in 1993, and an MD degree from Albert Einstein in 1999. He then went on to a residency program in Internal Medicine at Thomas Jefferson University Hospital, and finally to a Clinical Fellowship in Medical Oncology at MD Anderson. He joined the MD Anderson faculty in 2005 as Assistant Professor in GI Medical Oncology before moving to the Department of Investigational Cancer Therapeutics in 2007. He is now Douglas E Johnson Endowed Professor in the Department.

Ignace Vergote

Robert L. Coleman

Yvette Drew